NASDAQ · LFMDP
Healthcare · Medical - Pharmaceuticals
$21.14
Up+$0.11 (+0.52%)
Updated Nov 4, 2026, 7:49 PM
SID Score
4.3/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · LFMDP
1M range · 18 trading sessions · Daily adjusted prices
Prices through Nov 3, 2026
LFMDP closed at $21.14 after 18 trading sessions, down 9.46% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 3, 2026 | $21.17 | $22.05 | $20.93 | $21.1401 | 4.3K |
| Nov 2, 2026 | $21.12 | $22.00 | $21.12 | $21.29 | 2.27K |
| Oct 30, 2026 | $21.65 | $21.65 | $21.65 | $21.65 | 111 |
| Oct 28, 2026 | $22.00 | $22.00 | $21.52 | $21.52 | 985 |
| Oct 27, 2026 | $21.332 | $21.332 | $21.332 | $21.332 | 1.02K |
| Oct 26, 2026 | $21.625 | $21.625 | $21.04 | $21.60 | 2.4K |
| Oct 23, 2026 | $21.26 | $21.45 | $21.26 | $21.30 | 1.79K |
| Oct 22, 2026 | $20.9301 | $21.722 | $20.93 | $21.722 | 1.53K |
| Oct 21, 2026 | $22.11 | $22.11 | $21.49 | $21.49 | 3.23K |
| Oct 19, 2026 | $22.235 | $22.50 | $21.97 | $22.50 | 1.34K |
| Oct 16, 2026 | $22.182 | $22.182 | $22.182 | $22.182 | 832 |
| Oct 14, 2026 | $22.4426 | $22.4426 | $22.004 | $22.004 | 2.37K |
| Oct 13, 2026 | $22.44 | $22.48 | $22.44 | $22.48 | 635 |
| Oct 12, 2026 | $22.30 | $22.37 | $22.30 | $22.37 | 708 |
| Oct 9, 2026 | $22.48 | $22.48 | $22.38 | $22.38 | 359 |
| Oct 8, 2026 | $22.35 | $22.40 | $22.35 | $22.36 | 968.49 |
| Oct 7, 2026 | $21.965 | $22.40 | $21.965 | $22.40 | 1.77K |
| Oct 6, 2026 | $22.69 | $23.35 | $20.97 | $23.35 | 6.31K |
The latest Smart Investors Daily articles mentioning LFMDP.
Company
Market Activity
Research & News
LFMDP research
Company profile and research snapshot.
LifeMD Inc is a direct-to-patient telehealth company that provides a smarter, cost-effective, and more convenient way of accessing comprehensive, virtual healthcare. Its telehealth platform seamlessly integrates a clinician-centric electronic medical record (EMR) system, proprietary algorithms for case-load balancing and scheduling, customer relationship management functionality, remote and in-home lab testing, and digital prescription capabilities, patient-provider audio/video interfacing, cloud pharmacy fulfillment, and more. In addition to telehealth offerings, the company sells nutritional supplements and other over-the-counter products. The company has two operating segments: Telehealth and WorkSimpli. The company generates the majority of its revenue from the Telehealth segment.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 17, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 7, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 6, 2026 | B. Riley Securities | Buy | — |
| Aug 6, 2026 | BTIG | Buy | — |
| May 26, 2026 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Yahoo · Oct 26, 2026
Medifast (NYSE:MED) reported third-quarter 2026 revenue of $72 million, down 19.4% from a year earlier, as the company continued to face a sharp decline in its active earning coach base. Management said revenue was within its guidance range and marked a fourth consecutive quarter in which sales stab
Yahoo · Sep 16, 2026
T expands customer benefits with complimentary LifeMD memberships, offering virtual care, prescriptions and pharmacy services.
Yahoo · Jan 23, 2026
What the New LifeMD Price Target Tells You Analysts have updated their price target for LifeMD, marking a key shift in how the stock is being framed and discussed. This change reflects a refreshed view of the company that pulls together recent business developments and expectations already circulating in the market. Stay tuned to see how you can keep on top of future price target moves and the evolving narrative around LifeMD from here. Analyst Price Targets don't always capture the full...
Yahoo · Jan 14, 2026
Hims & Hers Health, Inc. (NYSE:HIMS) is among the 7 Best Beauty Stocks to Buy Right Now. TheFly reported on January 8, 2026, that BofA reduced the price target for Hims & Hers Health, Inc. (NYSE:HIMS) to $29 from $32. It retained an Underperform rating on the stock. The firm claims that the consensus expectations […]
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning LFMDP.
